AU2007264031C1 - S1P receptor modulators for treating multiple sclerosis - Google Patents

S1P receptor modulators for treating multiple sclerosis Download PDF

Info

Publication number
AU2007264031C1
AU2007264031C1 AU2007264031A AU2007264031A AU2007264031C1 AU 2007264031 C1 AU2007264031 C1 AU 2007264031C1 AU 2007264031 A AU2007264031 A AU 2007264031A AU 2007264031 A AU2007264031 A AU 2007264031A AU 2007264031 C1 AU2007264031 C1 AU 2007264031C1
Authority
AU
Australia
Prior art keywords
receptor modulator
amino
diol
propane
octylphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2007264031A
Other languages
English (en)
Other versions
AU2007264031A1 (en
AU2007264031B2 (en
Inventor
Peter C. Hiestand
Christian Schnell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36888144&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2007264031(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2007264031A1 publication Critical patent/AU2007264031A1/en
Publication of AU2007264031B2 publication Critical patent/AU2007264031B2/en
Priority to AU2011201844A priority Critical patent/AU2011201844B2/en
Application granted granted Critical
Publication of AU2007264031C1 publication Critical patent/AU2007264031C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2007264031A 2006-06-27 2007-06-25 S1P receptor modulators for treating multiple sclerosis Active AU2007264031C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2011201844A AU2011201844B2 (en) 2006-06-27 2011-04-21 S1P receptor modulators for treating multiple sclerosis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0612721.1 2006-06-27
GBGB0612721.1A GB0612721D0 (en) 2006-06-27 2006-06-27 Organic compounds
PCT/EP2007/005597 WO2008000419A1 (en) 2006-06-27 2007-06-25 S1p receptor modulators for treating multiple sclerosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2011201844A Division AU2011201844B2 (en) 2006-06-27 2011-04-21 S1P receptor modulators for treating multiple sclerosis

Publications (3)

Publication Number Publication Date
AU2007264031A1 AU2007264031A1 (en) 2008-01-03
AU2007264031B2 AU2007264031B2 (en) 2011-01-27
AU2007264031C1 true AU2007264031C1 (en) 2016-12-15

Family

ID=36888144

Family Applications (7)

Application Number Title Priority Date Filing Date
AU2007264031A Active AU2007264031C1 (en) 2006-06-27 2007-06-25 S1P receptor modulators for treating multiple sclerosis
AU2011201844A Active AU2011201844B2 (en) 2006-06-27 2011-04-21 S1P receptor modulators for treating multiple sclerosis
AU2013200356A Active AU2013200356B2 (en) 2006-06-27 2013-01-24 S1P receptor modulators for treating multiple sclerosis
AU2016266058A Abandoned AU2016266058A1 (en) 2006-06-27 2016-12-01 S1P receptor modulators for treating multiple sclerosis
AU2018202210A Abandoned AU2018202210A1 (en) 2006-06-27 2018-03-28 S1P receptor modulators for treating multiple sclerosis
AU2019219818A Abandoned AU2019219818A1 (en) 2006-06-27 2019-08-22 S1P receptor modulators for treating multiple sclerosis
AU2021202395A Abandoned AU2021202395A1 (en) 2006-06-27 2021-04-20 S1P receptor modulators for treating multiple sclerosis

Family Applications After (6)

Application Number Title Priority Date Filing Date
AU2011201844A Active AU2011201844B2 (en) 2006-06-27 2011-04-21 S1P receptor modulators for treating multiple sclerosis
AU2013200356A Active AU2013200356B2 (en) 2006-06-27 2013-01-24 S1P receptor modulators for treating multiple sclerosis
AU2016266058A Abandoned AU2016266058A1 (en) 2006-06-27 2016-12-01 S1P receptor modulators for treating multiple sclerosis
AU2018202210A Abandoned AU2018202210A1 (en) 2006-06-27 2018-03-28 S1P receptor modulators for treating multiple sclerosis
AU2019219818A Abandoned AU2019219818A1 (en) 2006-06-27 2019-08-22 S1P receptor modulators for treating multiple sclerosis
AU2021202395A Abandoned AU2021202395A1 (en) 2006-06-27 2021-04-20 S1P receptor modulators for treating multiple sclerosis

Country Status (20)

Country Link
US (3) US20100168078A1 (https=)
EP (4) EP2037906A1 (https=)
JP (8) JP2009541386A (https=)
KR (6) KR20140069178A (https=)
CN (2) CN103550195A (https=)
AU (7) AU2007264031C1 (https=)
BR (1) BRPI0713985A2 (https=)
CA (1) CA2653569C (https=)
DE (1) DE15177166T1 (https=)
DK (1) DK2959894T3 (https=)
ES (1) ES2887042T3 (https=)
GB (1) GB0612721D0 (https=)
HU (1) HUE059922T4 (https=)
LT (1) LT2959894T (https=)
MX (3) MX2008016133A (https=)
PL (1) PL2959894T3 (https=)
PT (1) PT2959894T (https=)
RU (1) RU2617502C2 (https=)
SI (1) SI2959894T1 (https=)
WO (1) WO2008000419A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0612721D0 (en) * 2006-06-27 2006-08-09 Novartis Ag Organic compounds
ES2707576T3 (es) * 2007-05-04 2019-04-04 Novartis Ag Uso de modulador del receptor S1P
KR20110020928A (ko) * 2008-06-20 2011-03-03 노파르티스 아게 다발성 경화증을 치료하기 위한 소아용 조성물
ES2526119T3 (es) 2008-08-18 2015-01-07 Novartis Ag Derivado de azetidina para el tratamiento de neuropatías periféricas
EP2177521A1 (en) 2008-10-14 2010-04-21 Almirall, S.A. New 2-Amidothiadiazole Derivatives
CN102256942B (zh) * 2008-12-18 2013-07-24 诺瓦提斯公司 1-(4-{1-[(e)-4-环己基-3-三氟甲基-苄氧基亚氨基]-乙基}-2-乙基-苄基)-氮杂环丁烷-3-甲酸的多晶型物
PT2676953T (pt) * 2008-12-18 2017-06-29 Novartis Ag Sal hemifumarato de ácido 1-[4-[1-(4-ciclo-hexil-3-trifluorometil-benziloxi-imino)-etil]-2-etil-benzil]-azetidino-3-carboxílico para utilização no tratamento de doenças mediadas por linfócitos
CA2747558A1 (en) * 2008-12-18 2010-07-15 Novartis Ag New salts
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
EP2210890A1 (en) 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
EP2305660A1 (en) 2009-09-25 2011-04-06 Almirall, S.A. New thiadiazole derivatives
US20110124605A1 (en) * 2009-11-20 2011-05-26 Shreeram Aradhye Use of an S1P Receptor Agonist
JP5939158B2 (ja) * 2009-11-24 2016-06-22 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 治療的有用性を有する受容体調節物質としての新規化合物
EP2343287A1 (en) 2009-12-10 2011-07-13 Almirall, S.A. New 2-aminothiadiazole derivatives
EP2366702A1 (en) 2010-03-18 2011-09-21 Almirall, S.A. New oxadiazole derivatives
EP2390252A1 (en) 2010-05-19 2011-11-30 Almirall, S.A. New pyrazole derivatives
BR112013017302B1 (pt) 2011-01-07 2021-12-07 Novartis Ag Composição farmacêutica em fase sólida
CN102120720B (zh) * 2011-01-25 2013-05-22 上海华升生物科技有限公司 盐酸芬戈莫德的合成新方法
PH12014500854A1 (en) * 2011-10-21 2021-08-09 Novartis Ag Dosage regimen for an s1p receptor modulator or agonist
EP2830338A4 (en) * 2012-03-23 2015-12-30 Nec Corp SUBSCRIBER SERVER, MONITOR SERVER, MOBILE TERMINAL, ASSOCIATED METHOD AND COMPUTER READABLE MEDIUM
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
CN102887829B (zh) * 2012-09-05 2014-07-02 中国科学院上海药物研究所 芬戈莫德粘酸盐及其晶体的制备方法和用途
US10675254B2 (en) 2013-10-11 2020-06-09 Teikoku Seiyaku Co., Ltd. Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
JP6401257B2 (ja) 2013-10-11 2018-10-10 テイコク ファーマ ユーエスエー インコーポレーテッド 局所用スフィンゴシン−１−リン酸受容体アゴニスト製剤及びその使用方法
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
WO2017120124A1 (en) 2016-01-04 2017-07-13 Auspex Pharmaceuticals, Inc. Azetidine modulators of the sphingosine 1-phosphate receptor
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
AU2020372647B2 (en) 2019-10-31 2026-02-05 Idorsia Pharmaceuticals Ltd Combination of a CXCR7 antagonist with an S1P1 receptor modulator
AU2022328858A1 (en) * 2021-08-20 2024-02-22 The Brain Protection Company PTY LTD Combinatorial therapies including implantable damping devices and therapeutic agents for treating a condition and associated systems and methods of use
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004113330A1 (en) * 2003-05-19 2004-12-29 Irm Llc Immunosuppressant compounds and compositions
WO2006058316A1 (en) * 2004-11-29 2006-06-01 Novartis Ag Dosage regimen of an s1p receptor agonist

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB612721A (en) 1946-02-11 1948-11-17 Richard William Bailey Improvements in combustion product power plant
US5604229A (en) 1992-10-21 1997-02-18 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
BR9207175A (pt) 1992-10-28 1995-12-12 Genentech Inc Composição contendo antagonista de fator de crescimento de célula endotelial vascular sequência aminoácida de anticorpo monoclonal polipeptídeo e método de tratamento de tumor em mamífero
DE69524962D1 (de) 1994-08-22 2002-02-14 Welfide Corp Benzolderivate und deren medizinische verwendung
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
ATE298740T1 (de) 1997-04-04 2005-07-15 Mitsubishi Pharma Corp 2-aminopropan-1,3-diol-verbindungen, ihre medizinische anwendung und zwischenprodukte zu ihrer synthese
ATE459616T1 (de) 1998-08-11 2010-03-15 Novartis Ag Isochinoline derivate mit angiogenesis-hemmender wirkung
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
WO2000037502A2 (en) 1998-12-22 2000-06-29 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
WO2000059509A1 (en) 1999-03-30 2000-10-12 Novartis Ag Phthalazine derivatives for treating inflammatory diseases
AR025068A1 (es) 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
GB0001930D0 (en) 2000-01-27 2000-03-22 Novartis Ag Organic compounds
PT1254138E (pt) 2000-02-09 2005-09-30 Novartis Ag Derivados de piridina que inibem a angiogenese e/ou o receptor de tirosina cinase do vegf
DE10033541C2 (de) 2000-07-11 2003-05-15 Litef Gmbh Lichtleitfaserspule für ein faseroptisches Sagnac-Interferometer und Verfahren zu ihrer Herstellung
WO2002006268A1 (en) 2000-07-13 2002-01-24 Sankyo Company, Limited Amino alcohol derivatives
WO2002018395A1 (en) 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
RU2199339C2 (ru) 2001-02-23 2003-02-27 Общество с ограниченной ответственностью "Биотех" Способ лечения рассеянного склероза
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
ATE448193T1 (de) 2002-01-18 2009-11-15 Merck & Co Inc ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
US7479504B2 (en) 2002-01-18 2009-01-20 Merck & Co., Inc. Edg receptor agonists
PL372103A1 (en) * 2002-05-16 2005-07-11 Novartis Ag Use of edg receptor binding agents in cancer
EP1511473B8 (en) * 2002-05-27 2013-07-24 Novartis AG Bis-aromatic alkanols
KR20080103117A (ko) * 2002-09-24 2008-11-26 노파르티스 아게 탈수초성 장애의 치료에 있어서의 스핑고신-1-포스페이트 수용체 아고니스트
KR20040048231A (ko) * 2002-12-02 2004-06-07 주식회사 두산 신생혈관생성 억제제 및 그를 포함한 암 치료용 키트
FR2848495B1 (fr) * 2002-12-12 2006-11-17 Sidel Sa Four pour chauffer au defile des ebauches de recipients en materiau thermoplastique
CA2521325C (en) 2003-04-08 2010-09-14 Novartis Ag Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
BRPI0410439A (pt) 2003-05-19 2006-06-06 Irm Llc compostos e composições imunossupressoras
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (en) 2004-05-05 2005-12-01 Adler, Richard, S. Systems and methods for protecting ship from attack on the surface or under water
EP1753442A2 (en) * 2004-06-10 2007-02-21 Regeneron Pharmaceuticals, Inc. Method of administering and using vegf inhibitors for the treatment of human cancer
US7972596B2 (en) * 2004-11-18 2011-07-05 Imclone Llc Antibodies against vascular endothelial growth factor receptor-1
BRPI0518105A (pt) * 2004-12-17 2008-11-04 Genentech Inc uso de antagonista da angiogênese e uso de anticorpo anti-vegf
RU2278687C1 (ru) 2005-06-16 2006-06-27 Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ ФЕДЕРАЛЬНОГО АГЕНТСТВА ПО ЗДРАВООХРАНЕНИЮ И СОЦИАЛЬНОМУ РАЗВИТИЮ" (ГОУ ВПО БГМУ РОСЗДРАВА РОССИИ) Способ лечения ремиттирующего рассеянного склероза
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
EP2633864A1 (en) 2008-07-25 2013-09-04 The Regents of the University of Colorado Clip inhibitors and methods of modulating immune function
GB2527550B (en) 2014-06-25 2016-09-21 Cook Medical Technologies Llc Implantable medical device with lumen constriction

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004113330A1 (en) * 2003-05-19 2004-12-29 Irm Llc Immunosuppressant compounds and compositions
WO2006058316A1 (en) * 2004-11-29 2006-06-01 Novartis Ag Dosage regimen of an s1p receptor agonist

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Brinkmann, V. et al, Journal of Biological Chemistry, 2002, 277(24):21453-21457 *

Also Published As

Publication number Publication date
KR20140069178A (ko) 2014-06-09
AU2007264031A1 (en) 2008-01-03
JP2009541386A (ja) 2009-11-26
AU2013200356A1 (en) 2013-02-14
PT2959894T (pt) 2022-10-18
KR20190030776A (ko) 2019-03-22
JP2013166761A (ja) 2013-08-29
KR20150122812A (ko) 2015-11-02
CA2653569C (en) 2016-06-21
JP2018109018A (ja) 2018-07-12
SI2959894T1 (sl) 2022-11-30
RU2569732C2 (ru) 2015-11-27
AU2007264031B2 (en) 2011-01-27
LT2959894T (lt) 2022-11-10
RU2013131176A (ru) 2015-01-20
ES2887042T1 (es) 2021-12-21
AU2016266058A1 (en) 2016-12-22
HUE059922T2 (hu) 2023-01-28
US9187405B2 (en) 2015-11-17
MX2022008950A (es) 2022-08-11
JP2019167352A (ja) 2019-10-03
JP2021035955A (ja) 2021-03-04
KR20170138583A (ko) 2017-12-15
JP2016185957A (ja) 2016-10-27
PL15177166T1 (pl) 2022-03-07
CN103550195A (zh) 2014-02-05
US20100168078A1 (en) 2010-07-01
ES2887042T3 (es) 2022-11-14
JP6931019B2 (ja) 2021-09-01
PL2959894T3 (pl) 2022-11-14
KR20210010956A (ko) 2021-01-28
AU2021202395A1 (en) 2021-05-20
HUE15177166T1 (hu) 2022-05-28
AU2011201844A1 (en) 2011-05-19
HK1214758A1 (en) 2016-08-05
US20110237682A1 (en) 2011-09-29
EP2698154A1 (en) 2014-02-19
CN101478961B (zh) 2013-11-27
DK2959894T1 (da) 2021-12-20
BRPI0713985A2 (pt) 2012-11-20
CA2653569A1 (en) 2008-01-03
JP7258832B2 (ja) 2023-04-17
WO2008000419A1 (en) 2008-01-03
HUE059922T4 (hu) 2024-05-28
RU2009102278A (ru) 2010-08-10
EP2959894B1 (en) 2022-10-12
EP3797765A1 (en) 2021-03-31
EP2959894A1 (en) 2015-12-30
EP2037906A1 (en) 2009-03-25
AU2011201844B2 (en) 2012-10-25
JP2023098949A (ja) 2023-07-11
DK2959894T3 (da) 2022-10-17
GB0612721D0 (en) 2006-08-09
AU2018202210A1 (en) 2018-04-26
CN101478961A (zh) 2009-07-08
AU2019219818A1 (en) 2019-09-12
JP2025016462A (ja) 2025-02-04
RU2617502C2 (ru) 2017-04-25
KR20090024281A (ko) 2009-03-06
US20140228446A1 (en) 2014-08-14
US8741963B2 (en) 2014-06-03
DE15177166T1 (de) 2022-01-27
MX2008016133A (es) 2009-01-15
MX2019012750A (es) 2020-02-03
AU2013200356B2 (en) 2016-09-29

Similar Documents

Publication Publication Date Title
AU2007264031C1 (en) S1P receptor modulators for treating multiple sclerosis
AU2006280138B2 (en) Liquid formulations
AU2008248648B2 (en) Use of S1P receptor modulator
HK1190934A (en) S1p receptor modulators for treating multiple sclerosis
HK1214758B (en) S1p receptor modulators for treating multiple sclerosis
RU2569732C9 (ru) Модуляторы рецептора s1p для лечения рассеянного склероза

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 04 AUG 2016

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 04 AUG 2016 .

GD Licence registered

Name of requester: NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 04 AUG 2016